[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Copenhagen University Hospital, Hvidovre\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":445},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,59,95,123,149,179,202,228,254,280,300,319,348,374,398,419],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":40,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200",false,"NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse","FEMALE","18 Years",{"count":20,"type":21},462,"ESTIMATED","OBSERVATIONAL","The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Pre-eclampsia","Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","ART","Neonatal Morbidity","Neonatal Mortality","Placental Abruption","Gestational Diabetes","Preterm Labor","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[25,41,31,42,43,44,45],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","RECRUITING","2026-04-07",{"date":49,"type":50},"2026-04-13","ACTUAL",{"date":52,"type":50},"2024-10-21",{"date":54,"type":21},"2028-06-01",{"name":56,"class":57},"Copenhagen University Hospital, Hvidovre","OTHER",6,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100617650","efficacy-of-bicarbonate-on-the-risk-of-assisted-delivery-in-nulliparous-women-with-prolonged-labour-100617650","NCT07321379","Efficacy of Bicarbonate on the Risk of Assisted Delivery in Nulliparous Women With Prolonged Labour","Efficacy of Bicarbonate on the Risk of Assisted Delivery in Danish Nulliparous Women With Prolonged Labour: a Double-blinded Parallel Randomized Controlled Trial (The ProLabour Trial)","ProLabour","Inclusion Criteria:\n\n* Age ≥18 years.\n* Danish or English speaking.\n* Cephalic presentation.\n* Gestational age ≥34+0 - \\\u003C42+0 (days +weeks) at onset of labour.\n* Normal foetal heart rate pattern in the 20 minutes prior to inclusion.\n* Spontaneous onset of labour or non-medical induced labour (balloon catheter and\u002For artificial rupture of membranes).\n* Active first stage of labour confirmed, according to Danish national guidelines: Cervical dilatation at ≥4 - \\\u003C10 cm with regular painful contractions.\n* Prolonged labour diagnosed, according to Danish national guidelines: Cervical dilatation progresses at less than 2 cm over a 4-hour period.\n\nExclusion Criteria:\n\n* Clinical suspicion of infection (2 confirmed temperatures ≥38.5°C with epidural, ≥38 °C without epidural, or broad-spectrum antibiotics initiated)\n* Significant medical comorbidity in the form of renal or heart condition, assessed case-by-case basis.\n* Serious obstetric complication\n* Known allergy or intolerance to sodium bicarbonate.\n* Ingestion of sodium bicarbonate in active labour prior to inclusion.\n* Current treatment with following medicines: Gabpabpentin, Tetracycline, Ketoconazole (NB! These medications are already generally advised contradicted against induring pregnancy)","50 Years",{"count":69,"type":21},1520,"INTERVENTIONAL",[72],"NA","The goal of this clinical trial is to learn if oral bicarbonate can treat prolonged labour in nulliparous women with prolonged labour.\n\nThe main question it aims to answer is: Do oral bicarbonate and restrictive oxytocin use reduce assisted delivery rate (emergency cesarean and vacuum\u002Fforceps delivery) in nulliparous women with prolonged labour.\n\nResearchers will compare bicarbonate and placebo (a look-alike substance that contains no drug) to see if bicarbonate works to treat prolonged labour.\n\nParticipants will:\n\n* drink bicarbonate or placebo\n* have cervical dilatation reassessed after 2 hours. If still slow progression, they will follow standard protocol for oxytocin augmentation\n* will receive a questionnaire 1 month post partum to assess birth experience\n\n1\u002F3 of participants will have amniotic fluid lactate measured at inclusion and after 2 hours",[75,76],"Prolonged Labor","Labor Dystocia",[78,79,80,81,82,83,84],"Labor","Bicarbonate","Caesarean section","Assisted birth","Oxytocin","Labor augmentation","Intrapartum","NOT_YET_RECRUITING","2026-01-08",{"date":88,"type":50},"2026-01-12",{"date":90,"type":21},"2026-02-01",{"date":92,"type":21},"2028-01-31",{"name":56,"class":57},3,{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":102,"minAge":103,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":70,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100590431","grace---graduated-response-for-advanced-copd-with-enhanced-support-100590431","NCT06967324","GRACE - Graduated Response for Advanced COPD With Enhanced Support","GRACE","Inclusion Criteria:\n\n* COPD\n* Exacerbation within the last year\n* Living in Høje Taastrup or Copenhagen\n* Cognitively relevant\n* ICECAP-SCM at least two scores of:\n\n  1. 1, 2\n  2. 1, 2\n  3. 1, 2\n  4. 1, 2\n  5. 1, 2, 3\n  6. 1, 2\n  7. 1, 2\n\nExclusion Criteria:\n\n* Dementia\n* Psychosis\n* Substance abuse\n* Hearing or speech impairment\n* Cancer\n* Receiving specialized palliative care or other similar interventions\n* Immediately dying","ALL","65 Years",{"count":105,"type":21},100,[72],"The aim of this study is to explore the feasibility and potential for a positive impact of a graduated response for advanced COPD with Enhanced Support. The study is a randomized controlled trial of:\n\n* systematic needs assessment\n* advance care planning\n* crossectoral virtual conferences. Researchers will compare quality of life and healthcare use of the intervention group with a control group that will be assessed for intervention need at the last follow-up.",[109],"COPD (Chronic Obstructive Pulmonary Disease)",[111,112,113],"COPD","palliative care","cross-sectoral","2025-12-09",{"date":116,"type":50},"2025-12-10",{"date":118,"type":50},"2025-08-07",{"date":120,"type":21},"2027-06-30",{"name":56,"class":57},1,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":4,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":70,"phases":132,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":122},"100540731","implementation-and-evaluation-of-telemedicine-in-cardiac-rehabilitation-100540731","NCT06320652","Implementation and Evaluation of Telemedicine in Cardiac Rehabilitation","Implementation and Evaluation of Telemedicine in Cardiac Rehabilitation - a Study on Health Literacy, Health Related Quality of Life, and Family Support","Inclusion Criteria:\n\n* Patients and their family members affiliated with the Department of Cardiology at Amager and Hvidovre Hospital and attending cardiac rehabilitation.\n* Patients diagnosed with ischemic heart disease, heart failure, persistent atrial fibrillation, and cardiac valve surgery.\n\nExclusion Criteria:\n\n* Patients with substantial language barriers and limited cognitive function.\n* Patients who can't use a smart phone, tablet, or computer.",{"count":131,"type":21},140,[72],"The overall aim is to develop and test the effect of a tailored patient and family focused cardiac tele rehabilitation intervention on health literacy by comparing it to standard care. Furthermore, to evaluate health-related quality of life, family support, and how the patients experience the communication and relationship with outpatient clinic nurses.",[135],"Cardiac Rehabilitation",[137,138,139,140],"Cardiac rehabilitation","Telemedicine","Video consultation","Home monitoring","2025-07-31",{"date":143,"type":50},"2025-08-05",{"date":145,"type":50},"2024-05-02",{"date":147,"type":21},"2027-08-31",{"name":56,"class":57},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":11,"sex":102,"minAge":4,"maxAge":4,"enrollmentInfo":157,"targetDuration":159,"studyType":22,"phases":4,"briefSummary":160,"conditions":161,"keywords":165,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":4},"100598097","risk-of-serious-adverse-events-following-unsupervised-vs-supervised-rehabilitation-after-knee-arthroplasty-100598097","NCT07067060","Risk of Serious Adverse Events Following Unsupervised vs Supervised Rehabilitation After Knee Arthroplasty","Risk of Serious Adverse Events Following Unsupervised vs Supervised Rehabilitation After Knee Arthroplasty: Protocol For An Emulated Noninferiority Trial (SAFE-T)","SAFE-T","Inclusion Criteria:\n\n* Adults undergoing primary total or unicompartmental knee arthroplasty (KA) for osteoarthritis in Denmark\n\nExclusion Criteria:\n\n* None",{"count":158,"type":21},40000,"2 Years","SUMMARY\n\nBackground:\n\nAfter knee arthroplasty (KA), rehabilitation is widely recommended, yet its clinical effectiveness-especially the need for supervision-has been challenged. While some argue that supervised rehabilitation may prevent serious adverse events (SAEs), previous trials show no superiority of rehabilitation, supervised or not, over no rehabilitation in terms of function. However, these trials were underpowered for safety outcomes. A large-scale evaluation is needed to determine if supervision impacts SAE risk, thereby informing rational use of health care resources.\n\nRationale for the proposed study. A conventional randomized trial to assess the safety of supervised versus unsupervised rehabilitation after KA would require an ethically and logistically infeasible sample size. By emulating such a trial using routinely collected registry data, the investigators can estimate the causal effect of supervision on the risk of serious adverse events-while accounting for confounding and preserving real-world relevance.\n\nActionable objective and hypothesis: To test whether unsupervised rehabilitation after knee arthroplasty increases the risk of serious adverse events over a 2-year period compared with supervised rehabilitation. The investigators hypothesize that unsupervised rehabilitation is non-inferior, defined as a hazard ratio for SAE risk below 1.4.\n\nDesign: Target trial emulation (TTE) using nationwide registry data to replicate the design and intent of a pragmatic randomized trial.\n\nSetting: Danish hospitals and municipalities. Patients: Adults undergoing primary total or unicompartmental knee arthroplasty for osteoarthritis, identified from Danish registries. The target trial assumes consecutive recruitment at hospital discharge to mirror real-world referral practices.\n\nInterventions: Referral to unsupervised home-based exercise or supervised municipal physiotherapy, defined by referral to rehabilitation pathways initiated at hospital discharge.\n\nMethods: Primary outcome is serious adverse events; secondary is number of hospital contacts. Propensity score-based weighting will adjust for confounding using patient and administrative covariates (e.g. age, BMI, comorbidities, surgery year), enabling causal inference from observational data.\n\nResults: Findings will inform clinical practice by estimating the comparative safety of unsupervised versus supervised rehabilitation after knee arthroplasty, based on real-world data from over 40,000 patients.\n\nLimitations: As with all non-randomized studies, residual confounding is possible. Despite adjustment strategies, causal interpretations should be made with caution due to reliance on observational data.\n\nConclusion: While TTE can provide valuable insight, the causal inferences made with TTE should be interpreted with caution, when not supported with an RCT.\n\nFunding: Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital is supported by a core grant from the Oak Foundation (OFIL-24-074).\n\nExternal funding: in process. Registration: TBD (registration on ClinicalTrials.Gov)",[162,163,164],"Total Knee Arthroplasty","Knee Arthroplasty","Unicompartmental Knee Arthroplasty",[166,167,168,169,170,171],"emulated target trial","total knee replacement","arthroplasty","serious adverse events","supervised rehabilitation","unsupervised rehabilitation","2025-07-29",{"date":141,"type":50},{"date":175,"type":21},"2026-01-01",{"date":177,"type":21},"2027-12-31",{"name":56,"class":57},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":122},"100584405","changes-in-perioperative-blood-volume-and-fluid-distribution-in-patients-undergoing-primary-total-hip-replacement-100584405","NCT06888908","Changes in Perioperative Blood Volume and Fluid Distribution in Patients Undergoing Primary Total Hip Replacement.","Perioperative Change in Blood Volume and Fluid Distribution in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients scheduled for an elective total hip arthoplasty (THA) in a standardized fast track setting.\n* Capable of participating in CO-rebreathing measurement\n* Age ≥ 18 years\n* Able to speak and understand Danish\n* Has provided written informed consent.\n\nExclusion Criteria:\n\n* Intraoperative blood loss exceeding 750 mL.\n* Perioperative need for a blood transfusion.\n* Confirmed or suspected coagulopathies.\n* Factors that make CO-rebreathing measurement impossible.\n* Known orthostatic intolerance.\n* American Society of Anesthesiologists physical status (ASA) classification ≥ 4.",{"count":187,"type":21},25,"Clinical assessment of bleeding and calculation of perioperative blood loss do not provide an accurate estimate of blood volume. This makes rational fluid management difficult, which is of high importance for patient-related outcomes. The availability of carbon monoxide(CO)-rebreathing allows for simple, non-invasive and precise measurement of changes in blood volume.\n\nThe purpose of the study is to investigate and describe changes in blood volume and fluid distribution perioperative in patients undergoing total hip arthroplasty. Furthermore, to investigate the association between changes in blood volume and incidence of orthostatic insufficiency.",[190],"Hip Arthroplasty Replacement",[192,193],"Blood loss","Blood volume","2025-03-17",{"date":196,"type":50},"2025-03-21",{"date":198,"type":21},"2025-03",{"date":200,"type":21},"2026-09",{"name":56,"class":57},{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":209,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":212,"conditions":213,"keywords":215,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":122},"100533347","the-effect-of-anti-il17-on-airway-hyperresponsiveness-and-resistance-100533347","NCT06224634","The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance","The Effect of Anti-IL17 on Airway Hyperresponsiveness and Resistance: a Longitudinal Cohort Study","Inclusion Criteria:\n\n* Patients planning to start treatment with anti-IL-17 antibodies\n\nExclusion Criteria:\n\n* Current pregnancy\n* FEV1 \\\u003C 1.5L or less than 60% of predicted value expected.\n* Previous anaphylactic shock or severe allergic reaction to medicine\n* Uncontrolled hypertension\n* Myocardial infarction or stroke within the last 3 months\n* Known aortic aneurysm\n* Recent eye surgery or risk of elevated intracranial pressure\n* Treatment with systemic corticosteroids within 6 weeks",true,{"count":211,"type":21},74,"This observational longitudinal cohort study aims to assess the effect of monoclonal antibodies targeting interleukin 17 (anti-IL-17) on airway hyperreactivity and airway resistance. The study involves adult participants suffering from dermatological or rheumatological illness, who are planning to start treatment with monoclonal antibodies targeting interleukin 17 as a part of the treatment of these diseases.\n\nThe primary outcome of this study will be changes in airway hyperresponsiveness to methacholine challenge reported as response-dose-ratio before and after initiation of anti-IL17 treatment regardless of presence of respiratory disease. Furthermore, the potential effect of anti-IL-17 on airway resistance will be assessed using conventional spirometry for measuring changes in FEV1 and Airwave oscillometry.\n\nA reduced degree of airway hyperreactivity and airway resistance after initiating ani-IL-17 could indicate effectiveness of anti-IL-17 in asthma patients which would have to be examined further in a population of asthma patients.",[214],"Asthma",[214,216,217,218,219],"Interleukin 17","ankylosing spondylitis","Psoriasis","Airway hyperresponsiveness","2025-03-14",{"date":222,"type":50},"2025-03-18",{"date":224,"type":50},"2024-08-02",{"date":226,"type":21},"2027-01",{"name":56,"class":57},{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":70,"phases":238,"briefSummary":239,"conditions":240,"keywords":243,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":122},"100582683","optimized-remission-in-alcohol-related-liver-cirrhosis-100582683","NCT06866496","Optimized Remission in Alcohol-related Liver Cirrhosis","Disease and Outcomes in Alcohol Related Liver Cirrhosis - A Prospective Cohort Study of Optimized Remission","Pro-ALC","Inclusion Criteria:\n\n* Clinical suspicion of cirrhosis related to use of alcohol, supported by biochemistry and ultrasound or other imaging techniques.\n* Informed written consent.\n\nExclusion Criteria:\n\n* The diagnosis of ALC is questioned with reasonable doubt.\n* Withdrawal of informed consent or no informed consent.",{"count":237,"type":21},350,[72],"The incidence of liver cirrhosis is increased fivefold for men and tripled for women in the last forty years.\n\nThe clinical course of liver cirrhosis includes complications of ascites, hepatic encephalopathy, variceal bleeding, kidney dysfunction, and infections that markedly worsen prognosis. These complications are driven by the development of portal hypertension in the liver. This progression to the 'decompensated' stage is considered a hallmark in the disease course, as the decompensation is associated with a markedly increased risk of further complications and death.\n\nIncreasing evidence indicate that active measures of treatment of the underlying cause of liver disease and removal of the toxic agents causing cirrhosis may slow disease progression or even induce regression of cirrhosis. This concept is described as hepatic recompensation.\n\nThere is a need for clinical studies investigating novel biomarkers with the capability to predict and monitor improvement in alcohol related liver cirrhosis, Between 75% and 80% of patients with liver cirrhosis in Denmark have or have had a harmful use of alcohol.\n\nAlcohol related liver disease (ArLD) has a major impact on patients' health and lives, and there is an unmet need to investigate treatment options that not only relieves complications, but also address the underlying pathways of alcohol related liver disease, also in severe stages of alcohol related cirrhosis (ALC). Factors such as BMI, female gender and mild portal hypertension are known to be associated with an increased likelihood of recompensation. Additional factors of genetic activation and molecular biomarkers from the proteome and lipidome have only attracted minor attention, and the impact of treating the drivers of decompensation, portal hypertension and alcohol use, and their impact on the natural cause of disease, have not been addressed.\n\nThe molecular pathophysiology of ArLD is incompletely understood. Characterization of the proteome dynamics across the spectrum of ALD could provide new insights into disease mechanisms of both progression and remission of disease.\n\nSeveral markers of inflammation and cytokines are involved in driving decompensation and has the potential to predict the risk of early death. It is unknown whether such markers can predict remission and recompensation in ALC and AH. Prospective studies investigating the associations between biomarkers of metabolism and prognosis, monitoring and efficacy og treatment in ALC are missing.\n\nThe overall objective of the present study is to investigate the molecular profile and pathways in persons with ALD to support personalized monitoring and follow-up in liver cirrhosis.\n\nThe study is an incidence cohort in which patients will be followed from diagnosis to death or withdrawal from the cohort. We will seek to include patients consecutively within three months of diagnosis.\n\nAll patients with a debut of alcohol related liver cirrhosis during admission regardless of the reason for admission, are eligible for inclusion.\n\nAll participants in this study will be offered the standard of care treatment. Alcohol cessation intervention including medical treatment of withdrawal symptoms and craving, referral to municipal offers of alcohol treatment, and motivational interviews is part of the treatment.\n\nThe study will contribute to a better characterization of advanced liver disease related to alcohol and contribute to an improved future organization of treatment- and rehabilitation offers to patients with liver disease. thorough characterization and consecutive inclusion will enhance our understanding on the incidence, prevalence and impact of ALC in the population, as well as the utilization of health care resources allocated to its treatment.\n\nA deeper insight into the molecular mechanisms of liver progression and remission will, in combination with clinical data, support our ability to predict outcomes in cirrhosis, facilitate personalized monitoring aiming at providing the right treatment for the right patient at the right time.",[241,242],"Cirrhosis of the Liver","Alcoholic Cirrhosis",[244,245],"cirrhosis","ArLD","2025-03-05",{"date":248,"type":50},"2025-03-10",{"date":250,"type":50},"2024-12-22",{"date":252,"type":21},"2034-12-31",{"name":56,"class":57},{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":263,"conditions":264,"keywords":268,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":122},"100456577","hemodynamic-measurements-of-macrocirculatory-and-perfusion-parameters-in-icu-100456577","NCT05225402","Hemodynamic Measurements of Macrocirculatory and Perfusion Parameters in ICU","Effects of Norepinephrine on Hemodynamic Measurements of Macrocirculatory and Perfusion Parameters in ICU Patients with Septic Shock","Inclusion Criteria:\n\n* Suspected or documented infection\n* Need for vasopressors to maintain mean arterial blood pressure (MAP) ≥65 mmHg\n* Serum lactate levels \\>2 mmol\u002FL\n* Norepinephrine infusion of \\> 0.2 mcg\u002Fkg\u002Fmin\n\nExclusion Criteria:\n\n* Absolute contraindication for esophageal doppler or urinary catheter insertion as noted in the patients' charts.\n* Severe valvular pathology and cardiac arrhythmias resulting in severe hemodynamic instability.\n* Lithium treatment\n* Treatment with other vasopressor or inotropic drugs.",{"count":262,"type":21},45,"In septic shock there is growing evidence of a state of hemodynamic \"disconnection\" with seemingly adequate macrocirculatory values despite actual microcirculation failing to meet cellular demand. Norepinephrine (NE) is recommended as first choice vasoactive agent for the treatment of septic shock. However, the dynamic effects of NE on macro- and microcirculation and perfusion parameters has not been described in detail in the context of septic shock, precluding rational individualized titration of NE and fluids, as recommended recently. In the present prospective observational multicenter study in adult septic shock patients, we intend to explore the effects of NE on preload dependency and tissue perfusion by evaluating the correlation and potential discrepancies between macro- and microcirculation both during titration of NE and after fluid resuscitation. The conclusions drawn from our study will contribute to the physiological knowledge necessary for establishing individualized evidence-based bedside management of hemodynamics in the setting of septic shock.",[265,266,267],"Septic Shock","Hemodynamic Instability","Vasoconstriction",[265,269,270,271,272],"Norepinephrine","Hemodynamic","Microcirculation","Intensive Care",{"date":274,"type":50},"2025-03-07",{"date":276,"type":50},"2022-03-08",{"date":278,"type":21},"2025-12-30",{"name":56,"class":57},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":122},"100476106","personalised-prediction-of-disease-course-in-ulcerative-colitis-using-multimodal-machine-learning---part-of-the-presager-project-100476106","NCT05479617","Personalised Prediction of Disease Course in Ulcerative Colitis Using Multimodal Machine Learning - Part of the Presager Project","Presager II","Inclusion criteria:\n\n* Signed informed consent\n* Diagnosis of UC for at least 1 year\n* Relapse due to UC.\n* First endoscopic and histological evaluation of the flare Exclusion criteria\n* Well-founded doubt that the flare is due to other than the patients UC",{"count":288,"type":21},400,"In patients achieving clinical remission following a flare, artificial intelligence can reliably predict a new flare within the next 12 months utilizing clinical and objective information at day 0 and week 8.\n\nSecondary endpoints:\n\n* An artificial intelligence model's precision in predicting a new flare within 2 and 3 years\n* An artificial intelligence model's precision to rule out patients who will not experience a new flare within 1, 2 and 3 year",[291],"Ulcerative Colitis","2025-02-25",{"date":294,"type":50},"2025-02-27",{"date":296,"type":50},"2022-06-20",{"date":298,"type":21},"2026-07",{"name":56,"class":57},{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":4},"100560516","initiation-of-exogenous-female-sex-hormones-and-airway-responsiveness-to-methacholine---a-prospective-cohort-study-100560516","NCT06578169","Initiation of Exogenous Female Sex Hormones and Airway Responsiveness to Methacholine - A Prospective Cohort Study","Inclusion Criteria:\n\n* Women aged 18 to 75 years\n* Planning to initiate HRT\u002FHC within next 30 days\n\nExclusion Criteria:\n\n* Gynecological, endocrinological or other disease affecting the ovarian cycle\n* FEV1 \\\u003C 60% of expected or \\\u003C 1.5L\n* Current hormonal medication\n* Pregnancy","75 Years",{"count":308,"type":21},300,"The project aims to investigate the effect of female sex hormone treatment (both contraceptive treatment and hormone therapy during menopause) on bronchial hyperreactivity in adult women. The study is a prospective cohort study involving 300 women, examining airway responsiveness before and after the initiation of hormone treatment, whether as hormone therapy in menopause or contraceptive treatment. Participants will be recruited from general practitioners in the Capital Region of Denmark. Lung function, bronchial hyperreactivity, airway inflammation, and body composition will be assessed before and after hormone treatment. Blood samples will also be collected and stored for later analysis of inflammation markers. The study will include women aged 18 to 75 who are about to begin hormone treatment.",[214],"2024-08-27",{"date":313,"type":50},"2024-08-29",{"date":315,"type":21},"2024-09-01",{"date":317,"type":21},"2027-09-01",{"name":56,"class":57},{"id":320,"slug":321,"hasResults":11,"nctId":322,"briefTitle":323,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":11,"sex":102,"minAge":4,"maxAge":4,"enrollmentInfo":326,"targetDuration":4,"studyType":70,"phases":328,"briefSummary":329,"conditions":330,"keywords":336,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":122},"100457394","family-centred-healthcare---zero-separation-and-couplet-care-100457394","NCT05236023","Family Centred Healthcare - Zero Separation and Couplet Care","Evaluation of a Family-centred Care Intervention Based on Zero Separation and Couplet Care","Inclusion Criteria:\n\n* Mothers with a treatment-requiring condition such as preeclampsia, bleeding, psychological diagnoses, discontinued milk production and infection.\n* Infant from gestational age 28 weeks with a treatment-requiring condition such as respiratory distress syndrome (with respiratory support including mechanical ventilation), hyperbilirubinemia, infection, and low blood sugar.\n\nExclusion Criteria:\n\n* Healthy mothers who does not need care and treatment, and has an infant admitted at NICU.\n* Mothers who are admitted at an adult intensive care unit due to severe sickness (severe preeclampsia with spasm, severe bleeding of 4-5 liter, and severe HELLP syndrome) - counting one-two mothers a year",{"count":327,"type":21},556,[72],"Today mother and infant are routinely separated directly after birth if there is a need of specialised treatment and care, despite of the significant and positive effects of skin-to-skin contact. Thus, there is a need of change in organizing the treatment and care in a way that minimizes separation.\n\nThe aim is to evaluate the implementation and effect of a complex family-centred intervention based 107 on zero separation and couplet care.\n\nThe intervention is rooted in the philosophy of family-centred care. Essentially, mother infant dyads will be admitted together, where they will receive couplet care by neonatal nurses. The study comprises a quasi-experimental trial and a qualitative process evaluation including a field study and two interview studies. Finally, a health economic evaluation will be conducted to assess the cost-effectiveness of this complex intervention. The intervention will take place at the Neonatal Intensive Care Unit at Hvidovre Hospital. The nurses will as a part of the intervention be educated to take care of both mother and infant and carry out the intervention.\n\nFive families with experiences from the Neonatal Intensive Care Unit and the Maternity Unit participates as patient and public representative in the project, as their experiences and ideas will provide an added value to the project.\n\nThis study contribute with a new perspective on how to organize the treatment and care of a newborn family in a Neonatal Intensive Care Unit. The study will be the first to examine zero separation and couplet care within sick mother-infant dyads. The study will provide knowledge about how an intervention consisting of zero separation and couplet care can be feasible and acceptable, and what kind of effect and impact it will provide. It is expected that the study as a whole may impact and profile clinical nursing, as well as benefitting public health.",[331,332,333,334,335],"Premature Birth","Post Partum","Infant","Mother-Child Relations","Family",[337,338,339],"preterm infants","zero-separation","Family centred care","2024-08-20",{"date":342,"type":50},"2024-08-21",{"date":344,"type":50},"2022-06-14",{"date":346,"type":21},"2026-08-31",{"name":56,"class":57},{"id":349,"slug":350,"hasResults":11,"nctId":351,"briefTitle":352,"officialTitle":353,"acronym":354,"eligibilityCriteria":355,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":356,"targetDuration":4,"studyType":70,"phases":358,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":122},"100522898","cryoneurolysis-for-acute-postoperative-pain-following-total-knee-arthroplasty-100522898","NCT06088602","Cryoneurolysis for Acute Postoperative Pain Following Total Knee Arthroplasty","The Effect of Cryoneurolysis for the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty in High Pain Responders - A Randomized, Participant- and Observer-masked, Sham-controlled Trial","CRISPP","Inclusion Criteria:\n\n* Age ≥ 18\n* Primary unilateral total knee arthroplasty\n* Ability to participate in the study (understand written and spoken Danish language, self-reported pain and satisfaction)\n* Signed written informed consent form\n* Pain (VAS 0-100 mm) ≥ 45 during a 5-meter walk test at 24 h (20-28h) postoperatively\n\nExclusion Criteria:\n\n* Ongoing treatment of systemic glucocorticoids or other immunosuppressant treatment apart from inhaled steroids\n* Insulin-dependent diabetes\n* Pregnancy or breastfeeding\n* Mental disability that could impair a patient's decision-making capability of giving informed consent and not enabling valid data collection.\n* Patients with known diagnoses of schizophrenia, ongoing psychosis, bipolar disease and\u002For a history of ongoing anti-psychotic treatment.\n* Patients with modulated pain-reception (experience) based on other diseases or injuries, e.g. spinal cord or brain injury, severe polyneuropathies or neurologic disorders.\n* Posttraumatic osteoarthritis as reason for total knee arthroplasty\n* Bleeding disorder\n* Localized infection in the treatment area\n* Cryoglobulinemia, cold urticaria, paroxysmal cold haemoglobinuria, or Raynaud's syndrome\n* Perioperative peripheral nerve block",{"count":357,"type":21},44,[72],"Cryoneurolysis is a regional anaesthetic technique that works by freezing peripheral sensory nerves. This technique can potentially provide analgesia after total knee arthroplasty (TKA). However, the technique is expensive and comprehensive. Pain 24 hours after surgery is associated with high amounts of late acute pain. Therefore, the aim of the current study was to compare the effect of postoperative cryoanalgesia with a sham treatment on acute postoperative pain in TKA patients with moderate to severe pain on the first postoperative day. The cryoanalgesia treatment will be performed 24 hours after surgery. Afterward, the patients will be followed for 24 weeks to determine the level of pain among other outcomes.",[361],"Acute Postoperative Pain",[363,364,365],"Cryoanalgesia","Acute postoperative pain","Total knee arthroplasty","2024-07-12",{"date":368,"type":50},"2024-07-16",{"date":370,"type":50},"2024-03-19",{"date":372,"type":21},"2025-10",{"name":56,"class":57},{"id":375,"slug":376,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":378,"acronym":379,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":70,"phases":383,"briefSummary":384,"conditions":385,"keywords":387,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":122},"100546702","virus-as-treatment-of-c-difficile-infection-vision-100546702","NCT06398379","Virus as Treatment of C. Difficile Infection (VISION)","VISION","Inclusion Criteria:\n\n* Recurrent C. difficile infection (first or second recurrence)\n* Understand danish\n\nExclusion Criteria:\n\n* Serious food allergy (anaphylaxis)\n* Other pathogenic bacteria\u002Fvirus in stool sample prior to inclusion\n* Inability to ingest capsules\n* Gastrointestinal perforation in the 180 days prior to inclusion\n* Previous treatment with FMT og rectal bacteriotherapy in the 180 days prior to inclusion\n* Short bowel syndrome\n* Pregnancy or planning of pregnancy\n* Participation in other clinical trial in the 30 days prior to inclusion\n* Stoma\n* Other condition where FMT is considered contraindicated",{"count":382,"type":21},40,[72],"Fecal Virome Transplantation (FVT) has in small studies shown benefit in the treatment of recurrent C. difficile infection.\n\nIn the VISION study we will treat patients with recurrent C. difficile infection with FVT capsules and compare the treatment with Fecal Microbiota Transplantation (FMT) capsules. Both will be following af standard treatment of antibiotics (Vancomycin)",[386],"Clostridium Difficile Infections",[388,389],"Fecal Virome Transplantation","Fecal Microbiota Transplantation","2024-04-30",{"date":392,"type":50},"2024-05-03",{"date":394,"type":21},"2024-05-01",{"date":396,"type":21},"2026-12-31",{"name":56,"class":57},{"id":399,"slug":400,"hasResults":11,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":209,"sex":102,"minAge":18,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":408,"conditions":409,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":122},"100388666","fatty-liver-disease-in-nordic-countries-100388666","NCT04340817","Fatty Liver Disease in Nordic Countries","Fatty Liver Disease in Nordic Countries (FLINC): a Prospective Cohort Study","FLINC","Inclusion Criteria:\n\n* Non-alcoholic fatty liver disease and\n* Healthy volunteers\n\nExclusion Criteria:\n\n* Other liver diseases than non-alcoholic fatty liver disease\n* Lack of informed consent",{"count":407,"type":21},634,"A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.",[410],"Non-Alcoholic Fatty Liver Disease","2020-04-09",{"date":413,"type":50},"2020-04-13",{"date":415,"type":50},"2017-09-01",{"date":417,"type":21},"2026-11-01",{"name":56,"class":57},{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":424,"acronym":4,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":102,"minAge":18,"maxAge":426,"enrollmentInfo":427,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":94},"100351255","fibro-inflammatory-progression-from-acute-to-chronic-pancreatitis-100351255","NCT03853447","Fibro-inflammatory Progression From Acute to Chronic Pancreatitis","Characterization of Fibro-inflammation During Progression From Acute to Chronic Pancreatitis","Inclusion Criteria:\n\n* Patients with CP (N=50) of any aetiology except gallstone induced CP: CP will be diagnosed based on MANNHEIM criteria .\n* Cohort 2: Patients with their first attack of AP of any aetiology except gallstone induced AP (N=50). The revised Atlanta criteria for acute pancreatitis will be used as diagnostic criteria.\n* Cohort 3: Patients with RAP (N=50) except gallstone induced RAP. RAP is defined as two or more cases of AP as diagnosed by the revised Atlanta Criteria.\n\nExclusion Criteria:","70 Years",{"count":428,"type":21},150,"Observational prospective study evaluating the developement of chronic pancreatitis based on imaging modalities as well as biochemical markers of inflammation, fibrosis and oxidative stress.",[431,432,433,434,435,436],"Pancreatitis","Acute Pancreatitis","Recurrent Pancreatitis","Chronic Pancreatitis","Inflammation","Fibrosis","2020-04-07",{"date":439,"type":50},"2020-04-08",{"date":441,"type":50},"2019-02-14",{"date":443,"type":21},"2041-01-01",{"name":56,"class":57},""]